Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001204750 | SCV001375971 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2022-10-28 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 936031). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the COL3A1 protein in which other variant(s) (p.Phe1456Leu) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with COL3A1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val1442Cysfs*7) in the COL3A1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 25 amino acid(s) of the COL3A1 protein. |